IO Biotech, Inc. (IOBT): Price and Financial Metrics


IO Biotech, Inc. (IOBT): $2.77

0.22 (+8.63%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add IOBT to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

IOBT Stock Price Chart Interactive Chart >

Price chart for IOBT

IOBT Price/Volume Stats

Current price $2.77 52-week high $9.77
Prev. close $2.55 52-week low $2.15
Day low $2.50 Volume 66,709
Day high $2.79 Avg. volume 132,375
50-day MA $2.70 Dividend yield N/A
200-day MA $3.84 Market Cap 79.82M

IO Biotech, Inc. (IOBT) Company Bio


IO Biotech, Inc., a clinical-stage biopharmaceutical company, develops disruptive immune modulating anti-cancer therapies in Denmark. The company's lead product candidate, IO102-IO103, is designed to target immunosuppressive proteins, such as Indoleamine 2,3-dehydrogenase (IDO), and programmed death ligand (PD-L1). It also develops IO112, a product candidate that contains a single Arginase 1-derived peptide designed to target T cells that recognize epitopes derived from Arginase 1 for the treatment of cancers. IO Biotech, Inc. was incorporated in 2021 and is based in Copenhagen, Denmark.


IOBT Latest News Stream


Event/Time News Detail
Loading, please wait...

IOBT Latest Social Stream


Loading social stream, please wait...

View Full IOBT Social Stream

Latest IOBT News From Around the Web

Below are the latest news stories about IO BIOTECH INC that investors may wish to consider to help them evaluate IOBT as an investment opportunity.

IO Biotech Announces Appointment of Devin Smith as General Counsel

Mr. Smith joins IO Biotech bringing over two decades of legal and compliance experience in the life science industriesNEW YORK, Jan. 23, 2023 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer vaccines based on its T-win® vaccine platform, today announced the appointment of Devin Smith as the company’s first General Counsel and Chief Compliance Officer. Mr. Smith will oversee all company legal activities and provid

Yahoo | January 23, 2023

IO Biotech Provides Business Update

Independent data monitoring committee recommends that the company’s Phase 3 trial evaluating IO102-IO103 in combination with pembrolizumab in first-line advanced melanoma patients continue without any modifications; the trial is enrolling patients at more than 80 active sites globally. Encouraging initial data reported from 9 evaluable non-small cell lung cancer patients from the company’s ongoing Phase 2 solid tumor basket trial evaluating IO102-IO103 in combination with pembrolizumab; the comp

Yahoo | January 9, 2023

ONCS, BVS and MIMO among mid-day movers

Gainers: Taboola TBLA +46%.Digital Brands Group (DBGI) +36%.Axsome AXSM +32%.Studio City MSC +27%.Cosmos (COSM) +25%.IO Biotech (IOBT) +22%.The Singing Machine Company (MICS)…

Seeking Alpha | November 28, 2022

Analyst Says IO Biotech''s Cancer Treatment Approach ''Differentiated''

HC Wainwright has initiated coverage on Denmark-based cancer firm IO Biotech Inc (NASDAQ: IOBT ) with a Buy rating and a price target of $10 . The company''s T-win platform works through a dual mechanism of action that involves the direct killing of immunosuppressive cells and modulation of the tumor microenvironment into a more pro-inflammatory anti-tumor environment. The company''s lead asset, IO102-IO103, is in development for several indications in solid tumors in combination with Merck & Co Inc (NYSE: MRK ) Ketyruda (pembrolizumab), with melanoma being the most advanced indication. The company is now evaluating the IO102-IO103 + pembrolizumab combo in … Full story available on Benzinga.com

Benzinga | November 21, 2022

Analyst Says IO Biotech's Cancer Treatment Approach 'Differentiated'

HC Wainwright has initiated coverage on Denmark-based cancer firm IO Biotech Inc (NASDAQ: IOBT) with a Buy rating and a price target of $10. The company's T-win platform works through a dual mechanism of action that involves the direct killing of immunosuppressive cells and modulation of the tumor microenvironment into a more pro-inflammatory anti-tumor environment. The company's lead asset, IO102-IO103, is in development for several indications in solid tumors in combination with Merck & Co Inc

Yahoo | November 21, 2022

Read More 'IOBT' Stories Here

IOBT Price Returns

1-mo 20.43%
3-mo 13.06%
6-mo -28.61%
1-year -67.60%
3-year N/A
5-year N/A
YTD 20.43%
2022 -64.06%
2021 N/A
2020 N/A
2019 N/A
2018 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.6567 seconds.